Prot #I1F-MC-RHBC(a): A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period

Project: Research project

StatusActive
Effective start/end date10/22/127/31/21

Funding

  • Parexel (Prot #I1F-MC-RHBC(a))
  • Eli Lilly and Company (Prot #I1F-MC-RHBC(a))